Physician profile
Steven M Levine
NPI 1992995583
$107,725.89
in general payments reported to CMS, 2019-2025
11 companies · $148 in 2025
The $148 reported for 2025 was less than what a typical Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $445).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $818 · 2020: $504 · 2021: $1,106 · 2022: $105K · 2023: $169 · 2024: $326 · 2025: $148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $644.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $643.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Surgical Innovation Associates, INC. | $104,375.13 | 2022 | |
| Allergan, INC. | $1,490.20 | 2019-2022 | |
| Sientra, INC. | $818.48 | 2019-2021 | |
| Tela Bio, INC. | $290.70 | 2023-2024 | Ovitex 2s, Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Motiva USA, LLC | $148.44 | 2025 | |
| Endo Pharmaceuticals INC. | $147.46 | 2019 | |
| Davol INC. | $138.17 | 2022 | |
| Stryker Corporation | $115.16 | 2024 | Na, Vsp System, Vsp Cranial, Medpor |
| Abbvie INC. | $89.53 | 2023-2024 | |
| Merz North America, INC. | $73.74 | 2019-2020 | |
| Apyx Medical Corporation | $38.88 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Levine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.